SUMMARY REPORT ICH MC TELECONFERENCE April 13, 2017

Similar documents
SUMMARY REPORT ICH MC TELECONFERENCE 26 September 2017

SUMMARY REPORT ICH MC TELECONFERENCE 24 January 2018

Minutes ICH Management Committee Meeting Montreal, Canada May 29 - June 1, 2017

FINAL MINUTES ICH Assembly May 31 & June 1, 2017, Montreal, Canada

FINAL MINUTES ICH Assembly Geneva, Switzerland November 2017

Trends in the development of regulatory systems by the example of ICH countries

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Overview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

ASSEMBLY AGENDA PAPERS. May 31 & June 1, 2017 Montreal, Canada

Portland, Oregon, USA (Portland Marriott Downtown Waterfront Hotel)

MEETING REPORT ICH Steering Committee November 2013, Osaka, Japan

ICH ASSOCIATION 2016 ANNUAL REPORT

Recent Development of ICH GCG

Yokohama, Japan (Yokohama Royal Park Hotel)

Consideration on Global Harmonization

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

ICH Regulators Forum. Dr Peter Arlett EU

Why do we need an addendum to ICH E6?

E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Rules of Procedure of the Assembly

Addendum to ICH E6 (R2)

STANDARD OPERATING PROCEDURE

Q11 Development and Manufacture of Drug Substances--Questions and Answers

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Conducting Monitoring Visits for Investigator-Initiated Trials (IITs)

Quality Risk Management ICH Q9

European network of paediatric research (Enpr-EMA)

Research Staff Training

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Standard Operating Procedures

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Regional Update ASEAN PPWG

Role and Vision of PMDA

Topical Peer Review 2017 Ageing Management of Nuclear Power Plants

1. Introduction, purpose of this Standard Operating Procedure (SOP)

Now We are Getting to the Hard Parts: An Analysis Files Perspective

Standard Operating Procedures (SOP) Research and Development Office

Clinical Study Risk Assessment

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

Annual report of the Good Clinical Practice Inspectors Working Group 2016

Work plan for GCP Inspectors Working Group for 2018

International trend on medical device regulatory convergence

SADC Collaborative Medicines Registration Initiative (Zazibona)

ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY

European network of paediatric research (EnprEMA)

Overview ICH GCP E6(R2) Integrated Addendum

Toward Greater Scientific Rigor

BRISTOL-MYERS SQUIBB DATA SHARING INDEPENDENT REVIEW COMMITTEE (IRC) CHARTER

Lao Business Forum: Improving the business environment through constructive dialogue

International Federation of Pharmaceutical Manufacturers & Associations. IFPMA Code of Practice

PMDA EPOCH Toward 2020

IMDRF Project: List of international standards recognized by IMDRF management committee members

Adverse Event Reporting

Submission of a clinical trial for access to ECRIN services Notice to the Applicant

GPP Subcommittee Meeting

GCP Inspection by PMDA

BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES

1. Introduction, purpose of this Standard Operating Procedure (SOP)

European Medicines Agency Inspections ANNEX V TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: PHASE I UNITS

Innovation, Information, Evidence and Research INNOVATING AND EMPOWERING PEOPLE FOR HEALTH

Global strategy and plan of action on public health, innovation and intellectual property

BASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna

Auditing of Clinical Trials

TRAINING REQUIREMENTS FOR RESEARCH STAFF, INCLUDING GOOD CLINICAL PRACTICE (GCP)

Updated Proposal by Brazil and France as co-chairs of the REDD+ Partnership:

1. INTRODUCTION 2. SCOPE 3. PROCESS

Preliminary Questionnaire

Unofficial copy not valid

International Regulatory Harmonization Amid Globalization of Biomedical Research & Medical Product Development: An Institute of Medicine Workshop

Final Draft Agenda Sixteenth meeting of the Forum for Exchange of Information on Enforcement (Forum-16) October 2013

Surveying and Evaluating Ethical Review Practices

- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

- Proposal for a Regulation on HTA- DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation

Document Title: Version Control of Study Documents. Document Number: 023

NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES

EU Stress Tests and National Action Plans

PATHWAYS FOR STANDARDS DEVELOPMENT. Developing internationally aligned Australian Standards in the national interest

Standardization Activities of SMIIC Technical Committees (TCs)

Document Title: Training Records. Document Number: SOP 004

Item 4. Report from the last UN Statistical Commission

Teleconference Course Materials You may duplicate this for each person attending the conference.

Provisional agenda (annotated)

Computer Validation Initiative Committee Membership Requirements

D6.3 Communication management routines and infrastructure implemented

The place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

VACANCY ANNOUNCEMENT. Senior Grants Officer for Asia (Ref: )

European network of paediatric research (EnprEMA)

International Pharmaceutical Federation Fédération internationale pharmaceutique. Standards for Quality of Pharmacy Services

GCP Training for Research Staff. Document Number: 005

Background Paper for the Meeting of National Focal Points on Improving Future National Reporting to the Commission on Sustainable Development

PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA 6 TH TECHNICAL COMMITTEE MEETING NOVEMBER 2015 ADDIS ABABA, ETHIOPIA CONCEPT NOTE

Looking at our Achievements and the Way Forward. The 5 th pharmaceutical compliance congress & best practices forum Istanbul - Turkey

Scientific Advice and Protocol Assistance at the EMEA

Risk Assessment and Monitoring

Post- Fukushima accident. Action plan. Follow-up of the peer review of the stress tests performed on European nuclear power plants

STANDARD OPERATING PROCEDURE

IECEx OPERATIONAL DOCUMENT

STANDARD OPERATING PROCEDURE 24. Training Records

Transcription:

Ref.: MC2017/04 May 29, 2017 SUMMARY REPORT ICH MC TELECONFERENCE April 13, 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, 1211 Geneva 20, Switzerland Telephone: +41 (22) 338 32 06 - admin@ich.org, http://www.ich.org

LIST OF PARTICIPANTS: ICH Management Committee Members/Observers Ms. Lenita Lindström EC/EMA Dr. Spiros Vamvakas EC/EMA Dr. Sabine Luik EFPIA Mr. Pär Tellner EFPIA Dr. Theresa Mullin (Chair) Ms. Joan Blair Ms. Pujita Vaidya Dr. Celia Lourenco Health Canada Ms. Catherine Parker Health Canada Dr. Hironobu Hiyoshi JPMA Dr. Masafumi Yokota JPMA Dr. Toshiyoshi Tominaga (Vice Chair) MHLW/PMDA Dr. Nobumasa Nakashima MHLW Mr. Naoyuki Yasuda MHLW/PMDA Dr. Peter Honig PhRMA Mr. Jerry Stewart PhRMA Ms. Cordula Landgraf Swissmedic ICH MC Coordinators Mr. Pär Tellner Ms. Amanda Roache Mr. Nick Orphanos Mr. Mitsuo Mihara Mr. Fumihito Takanashi Ms. Camille Jackson EFPIA Health Canada JPMA MHLW PhRMA Technical Coordinators: Dr. Michelle Limoli Ms. Chieko Hirose MHLW/PMDA Other Participants: Dr. Tomas Salmonson Dr. Sarah Adam Dr. Gabriela Zenhäusern EC IFPMA WHO ICH Secretariat: Dr. Dawn Ronan Dr. Isabelle Güller Dr. Véronique Kuntzelmann 1

SUMMARY REPORT MC Chair: Dr. Theresa Mullin, MC Vice-Chair: Dr. Toshiyoshi Tominaga, MHLW/PMDA 1. ADOPTION OF THE AGENDA The agenda was adopted without any comments. 2. ORGANISATION OF MONTREAL MEETING The MC noted the following key dates for the preparation of the Montreal meeting: By/at latest May 1: The draft Assembly Agenda will be circulated to the Assembly; By/at latest May 17: The Assembly Agenda Papers Package, including background documents will be circulated to the Assembly. The MC supported the draft Assembly Agenda prepared by the ICH Secretariat pending minor updates in view of the outcome of the teleconference. Following the teleconference, the ICH Secretariat will share the final draft Assembly Agenda with the Assembly Chair and Vice Chair for their support and thereafter with the MC for any final comment before sending to the Assembly Members and Observers. 3. REVISION OF ICH ARTICLES OF ASSOCIATION & ASSEMBLY RULES OF PROCEDURE The MC was updated on the comments received from MC Members on the proposed revisions to the ICH Articles of Association and Assembly Rules of Procedure and the main changes made in view of these comments. The MC noted these changes included those related to keeping the size of ICH meetings manageable. The MC confirmed support for many of the changes, but agreed further discussion was needed on some items. The MC supported to update the proposed revisions to the Articles of Association and Assembly Rules of Procedures based on its discussion, leaving aside those items that would require further discussion. This would enable the circulation of the proposed revisions to the Assembly for its consideration ahead of the Montreal meeting. The MC noted that some revisions to the MC Rules of Procedure would be proposed for consideration by the MC in Montreal. Revised versions of the Articles of Association and Assembly Rules of Procedure will be shared with the MC for its support, following which these revisions will be proposed to the Assembly ahead of the Montreal meeting for consideration by the Assembly for approval in Montreal. In Montreal, the MC will be invited to discuss proposed revisions to the MC Rules of Procedure, in addition to items raised in discussion of the revisions to the Articles of Association and Assembly Rules of Procedure which were considered as needing further consideration. The MC supported scheduling 1 hour for this topic at both the MC and Assembly meetings in Montreal. 2

4. NEW TOPIC PROPOSALS AND STRATEGIC DISCUSSIONS The MC supported allocating 90 minutes at the MC meeting and 60 minutes at the Assembly meeting in Montreal for discussion regarding the following items. New Topics Subcommittee The MC was updated on the activities of the New Topic Subcommittee in consideration of the 16 New Topic Proposals received in January. While noting that some topics still needed further discussion by the MC and the Assembly, the MC supported the following short-list of 8 topics * to be sent to the Assembly by May 1, pending prioritization by the MC ahead of Montreal, based on which a recommendation would be made to the Assembly regarding the progression of these topics: 1. Continuous Manufacturing 2. Quality Overall Summary 3. Analytical Procedure Development and Q2 Revision 4. E8 Revision 5. E2A 6. Natural History Studies 7. Outlier Investigation 8. Paediatric Extrapolation The MC supported the short-list of 8 topics which will be: (1) sent to the Assembly by May 1; and (2) scored and prioritized by the MC by May 1, to allow a compilation to be provided to the MC ahead of the May 16 MC teleconference, when the MC should finalize its recommendation to the Assembly. * GCP Renovation The MC was updated on the 22 comments received on the Reflection Paper on GCP Renovation. The MC noted that the E8 revision would be progressed first. The MC supported that the analysis of the comments will be provided to the Assembly in the Agenda Papers Package ahead of Montreal. Adaptive Clinical Trials The MC was updated on the advancement of the Adaptive Clinical Trials topic. The MC supported that further discussion of the Adaptive Clinical Trials topic takes place at the Geneva meeting in November 2017, with consideration of the progress of existing working groups activities, with discussion of the proposal with the Assembly thereafter. Strategic Discussions The MC discussed the organisation at the Montreal meeting of discussion on strategic topics to progress, further to the Strategic Portfolio approach presented in November 2016, and the general outline discussed in June 2016. * Post-Meeting Note: For the formal record it is noted that while these 8 topics were sent to the Assembly on May 1, 2017, MHLW/PMDA subsequently raised a concern, highlighting that at the TC on April 13, there had been discussion that all 14 proposals should be sent to the Assembly and prioritised by the MC. Noting this confusion at the subsequent MC TC on May 16, the MC agreed to further discuss in Montreal next steps for these other proposals which had not been sent to the Assembly and had not been prioritised by the MC. 3

The MC noted that material will be sent to the Assembly ahead of the Montreal meeting to support presentation of the progress made on the strategic topic Compliance of Reliability for Electronic Records. The MC noted that a Quality Reflection Paper, will be shared with the MC by May 1 for comments prior to sharing with the Assembly. The MC supported further discussion in Montreal on strategic themes and the process for progressing work on new topics (i.e., progression in view of strategic themes versus individual topics). 5. ICH MEMBERSHIP AND OBSERVERSHIP The MC was updated on applications currently under review. The MC supported 30 min for discussion at both the MC and Assembly meetings in Montreal. 6. SOPS FOR EWGS/IWGS The MC noted that prior to the Montreal meeting, the SOP Subcommittee planned to make a recommendation for MC approval on proposed revisions to the SOPs for WGs to address items including the procedures on how experts join a working group and how to manage the size of the working groups appropriately. The MC supported that the SOPs for EWGs/IWGs will be discussed during 30 min at the MC meeting and during 15 min at the Assembly meeting in Montreal. 7. ICH FINANCIAL MATTERS The MC was updated on the activities of the Financial Subcommittee in preparation of the Montreal meeting, where the Assembly will be invited to approve the 2018 ICH Budget and the 2016 audited accounts of the Association, and will be updated on other items including: a multi-year budget plan; a proposal for a participation fee for Observers and cash flow. The MC noted that the Financial Subcommittee was also working on an options paper regarding the future organisation of ICH meetings, but would propose to discuss this topic separately to financial matters in Montreal in view of the fact that it extends beyond financial considerations. The MC noted that the Financial Subcommittee would share with it the documents for discussion in Montreal following its next teleconference on April 26, 2017. The MC supported that financial matters be discussed during 60 min at the MC meeting and during 30 min at the Assembly meeting in Montreal. The MC supported that the future organisation of ICH meetings be discussed during 45 min at the MC meeting and 15 min during the Assembly meeting in Montreal. 4

8. ICH TRAINING STRATEGY The MC noted that in Montreal the Training Subcommittee will provide an update on the progress of the pilot supported by the MC in Osaka in November 2016 for the Training Subcommittee to partner with a small group of training providers. The MC was informed that a more substantial discussion was planned for the next ICH meeting in Geneva in November 2017 after the completion of many of the pilot training programmes. The MC confirmed that the status of the Training Subcommittee s activities will be presented during 10 min at both the MC and the Assembly meetings in Montreal. 9. ICH COMMUNICATION The MC noted that in Montreal, the Communication Subcommittee will provide an update on the activities of the ICH Communication Subcommittee and seek MC formal approval of the final Communication and Stakeholder Engagement Plan for 2017-2018 and Transparency Policy. The MC noted the need to confirm with the Communication Subcommittee the time needed for discussion at both the MC and the Assembly meetings in Montreal. 10. ICH OPERATIONAL/SECRETARIAT MATTERS The ICH Secretariat informed the MC on the status of the ICH Guideline Implementation table, and the MC noted other items for discussion in Montreal including: preparation for the expansion of the MC; IPRF cooperation; and general ICH meeting organisation. The MC supported ICH Secretariat efforts to complete the Implementation table for provision to the Assembly with information from all ICH Regulatory Members (with Observer Members to also be invited to share information if they wish). The MC supported further discussion at its next teleconference on May 16, 2017 on the preparation of a discussion with the Assembly on Guideline Implementation in Montreal. 11. ICH INFORMAL E19 WG The MC noted the progress made towards developing the E19 Concept Paper and Business Plan and that further time was needed by the informal WG to finalise these items for MC approval. The MC confirmed that the E19 informal WG will meet in Montreal to finalize the Concept Paper and Business Plan. Once the E19 Concept Paper and Business Plan will be endorsed by the MC at the Montreal face-to-face meeting, the E19 Expert Working Group will be established. 5

12. DATES OF NEXT TELECONFERENCE AND MEETINGS Teleconference Ahead of Montreal Meeting: May 16, 2017 MC TC (Policy/Procedures) Face-to-Face ICH Meetings: May 27 June 1, 2017 Montreal, Canada November 11-16, 2017 Geneva, Switzerland June 2-7, 2018 Kobe, Japan 6